Primecap Management Co. CA Sells 73,220 Shares of Illumina, Inc. $ILMN

Primecap Management Co. CA cut its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,885,279 shares of the life sciences company’s stock after selling 73,220 shares during the period. Primecap Management Co. CA’s holdings in Illumina were worth $179,045,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Parkside Financial Bank & Trust raised its stake in shares of Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after buying an additional 115 shares during the period. Quent Capital LLC purchased a new stake in Illumina in the 3rd quarter worth approximately $29,000. NewSquare Capital LLC increased its holdings in Illumina by 604.9% in the 2nd quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after acquiring an additional 369 shares in the last quarter. Mather Group LLC. bought a new stake in Illumina during the 3rd quarter worth approximately $46,000. Finally, Evelyn Partners Investment Management LLP lifted its holdings in Illumina by 4,927.3% during the second quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company’s stock valued at $49,000 after purchasing an additional 542 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Insider Activity at Illumina

In other Illumina news, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the transaction, the insider owned 17,887 shares in the company, valued at $2,434,241.83. This trade represents a 1.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the sale, the senior vice president directly owned 16,321 shares in the company, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.60% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on ILMN shares. Guggenheim raised their price objective on shares of Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Illumina in a report on Monday, December 29th. Zacks Research cut Illumina from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 31st. Piper Sandler lowered their price objective on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research report on Monday, February 9th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Illumina in a research note on Wednesday, January 7th. Six analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Illumina currently has an average rating of “Hold” and a consensus target price of $127.94.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina launched TruPath™ Genome and unveiled a NovaSeq X roadmap at AGBT, positioning the company to capture higher‑value whole‑genome and instrument upgrade demand. Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics
• Positive Sentiment: Illumina highlighted customer breakthroughs using Connected Multiomics (spatial transcriptomics, epigenomics, proteomics), which supports higher‑margin consumable sales and strengthens clinical/research adoption narratives. Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics
• Positive Sentiment: Takara Bio USA announced a collaboration with Illumina on a single‑cell spatial transcriptomics workflow presented at AGBT, expanding ecosystem partnerships and accelerating adoption in translational oncology and diagnostics. Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026
• Positive Sentiment: Market research forecasts strong growth in preimplantation genetic testing (PGT) through 2030, supporting long‑term demand for NGS platforms and reagents that Illumina supplies. Preimplantation Genetic Testing Market Research and Global Forecast Report 2025-2030
• Neutral Sentiment: Analysts and publications are comparing Illumina to competitors like Tempus (TEM), highlighting strong TEM revenue growth and AI oncology momentum—underscoring competitive risk but also validating the sector’s growth tailwinds. TEM vs. ILMN: Which MedTech Stock Offers Greater Upside?
• Neutral Sentiment: A separate analyst piece reviews Illumina’s recent share rebound and longer‑term volatility, reminding investors to weigh valuation and execution risk despite the near‑term product news. Assessing Illumina (ILMN) Valuation After Recent Share Price Rebound And Longer Term Volatility

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $127.40 on Friday. The company has a market cap of $19.48 billion, a P/E ratio of 23.38, a P/E/G ratio of 2.33 and a beta of 1.45. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $155.53. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The firm’s fifty day moving average is $135.13 and its two-hundred day moving average is $117.84.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same quarter last year, the business posted $0.95 earnings per share. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.